Molecular genetic features of the head and neck (upper aerodigestive tract) mucosal melanoma


Cite item

Full Text

Abstract

Mucosal melanoma is a rare and aggressive neoplasm of melanocytic origin. To date, in literature only few retrospective series and case reports have been reported on mucosal melanoma. Despite melanoma’s common histological origin,molecular biology of upper aerodigestive tract mucosal melanoma has some specific features compared with those of cutaneous melanomas. Taking into concideration the tremendous number of studies of prognostic molecular markers in cancer, only a few such markers have entered clinical practice in mucosal melanoma. The incidence of activating mutations in the BRAF, C-KIT and N-RAS oncogenes in mucosal melanoma is quite different from cutaneous melanoma: upper aerodigestive tract melanoma is characterized by high incidence of C-KIT and N-RAS mutations, BRAF mutations are uncommon. The most frequently studied markers in upper aerodigestive tract mucosal melanoma and prospectives of targeted therapy are reviewed in this article. A better comprehension of the pathogenesis of disease, in particular its molecular aberrations, can provide important insights into targets for future therapies.

About the authors

A V Ignatova

Russian Medical Academy of Postgraduate Education of the Ministry of Health of the Russian Federation

Email: annasurge@gmail.com
врач-онколог, каф. онкологии ФГБОУ ДПО РМАНПО 123995, Russian Federation, Moscow, ul. Barrikadnaya, d. 2/1

References

  1. Thompson L.D, Wieneke J.A, Miettinen M. Sinonasal tract and nasopha - ryngeal melanomas: a clinicopathologic study of 115 cases with a pro - posed staging system. Am J Surg Pathol 2003; 27: 594-611.
  2. Patel S.G, Prasad M.L, Escrig M. Primary mucosal malignant melanoma of the head and neck. Head Neck 2002; 24: 247-57.
  3. Owens J.M, Roberts D.B, Myers J.N. The role of postoperative adjuvantradiation therapy in the treatment of mucosal melanomas of the head and neck region. Arch Otolaryngol Head Neck Surg 2003; 129: 864-8.
  4. Weber C.O. Surgical Experience and Research, in Addition to Interesting Observations from the Surgical Clinic and the Protestant Hospital Bonn. Berlin: G Reimer, 1859; p. 304-5.
  5. Mc Laughlin C.C, Wu X.C, Jemal A et al. Incidence of noncutaneous melanomas in the US. Cancer 2005; 103: 1000-7.
  6. Manolidis S, Donald P.J. Malignant mucosal melanoma of the head and neck: review of the literature and report of 14 patients. Cancer 1997; 80: 1373-86.
  7. Lourenço S.V, Sangueza M, Sotto M.N et al. Primary oral mucosal melanoma: a series of 35 new cases from South America. Am J Dermatopathol 2009; 31: 323-30.
  8. Anderson L.J, Berthelsen A, Hansen H.S. Malignant melanoma of the upper respiratory tract and the oral cavity. J Otolaryngol 1992; 21: 180-5.
  9. Gorsky M, Epstein J.B. Melanoma arising from the mucosal surfaces of the head and neck. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1998; 86: 715-9.
  10. Trap T.K, Fu Y, Calcaterra T.C. Melanoma of the nasal and paranasal sinus mucosa. Arch Otolaryngol Head Neck Surg 1987; 113: 1086-9.
  11. Papaspyrou G, Garbe C, Schadendorf D et al. Mucosal melanomas of the head and neck: new aspects of the clinical outcome, molecular pathology, and treatment with c - kit inhibitors. Melanoma Res 2011; 21: 475-82.
  12. Lourenco S.V, Fernandes J.D, Hsieh R et al. Head and neck mucosal melanoma: a review. Am J Dermatopathol 2014; 36 (7): 578-87. doi: 10.1097/DAD.0000000000000035.
  13. Miller A.J, Mihm M.C. Melanoma. N Engl J Med 2006; 355 (1): 51-65.
  14. Berger M.F, Garraway L.A. Applications of genomics in melanoma oncogene discovery. Hematol Oncol Clin North Am 2009; 23 (3): 397-414.
  15. Long G.V, Menzies A.M, Nargial A.M et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol 2011; 29 (10): 1239-46.
  16. Rajakulendran T, Sahmi M, Lefrançois M et al. A dimerization - dependent mechanism drives RAF catalytic activation. Nature 2009; 461 (7263): 542-5.
  17. Davies H, Bignell G.R, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417 (6892): 949-54.
  18. Lovly C.M, Dablman K.B, Fobn L.E et al. Routine multiplex mutational profiling of melanomas enables enrollment in genotype - driven therapeutic trials. PLoS One 2012; 7 (4): e35309.
  19. Lin K, Baritaki S, Militello L et al. The role of B-RAF mutations in melanoma and the induction of EMT via dysregulation of the NF-KB/Snail/RKIP/PTEN circuit. Genes Cancer 2010; 1 (5): 409-20.
  20. Wan P.T, Garnett M.J, Roe S.M et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 16 (6): 855-67.
  21. Мазуренко Н.Н. Генетические особенности и маркеры меланомы кожи. Успехи молекулярной онкологии. 2014; 1 (2): 26-35. doi: 10.17650/2313-805X.2014.1.2.26-35.
  22. Turri-Zanoni M, Medicina D, Lombardi D et al. Sinonasal mucosal melanoma: molecular profile and therapeutic implications from a series of 32 cases. Head Neck 2013; 35: 1066-77.
  23. Buery R.R, Siar C.H, Katase N et al. NRAS and BRAF mutation frequency in primary oral mucosal melanoma. Oncol Rep 2011; 26: 783-7.
  24. Troussier I, Baglin A-C, Marcy P-Y. Mélanomes muqueux de la tête et du cou état actuel des pratiques et controverses. Bulletin du Cancer.
  25. Carvajal R.D, Spencer S.A, Lydiatt W. Mucosal melanoma: a clinically and biologically unique disease entity. J Natl Compr Cancer Netw JNCCN 2012; 10 (3): 345-56.
  26. Beadling C, Jacobson-Dunlop E, Hodi F.S et al. KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 2008; 14 (21): 6821-28. doi: 10.1158/1078-0432.CCR-08-0575.
  27. Hauschild A et al. Dabrafenib in BRAF - mutated metastatic melanoma: a multicentre, open - label, phase 3 randomised controlled trial. Lancet 2012; 380: 358-65. doi: 10.1007/s11912-012-0244-x.
  28. Kim H.S, Kim E.K, Jun H et al. Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. BMC Cancer 2010; 10: 167. doi: 10.1186/1471-2407-10-167.
  29. Bartell H.L, Bedikian A.Y, Papadopoulos N.E et al. Biochemotherapy in patients with advanced head and neck mucosal melanoma. Head Neck 2008; 30 (12): 1592-8. doi: 10.1002/hed.20910.
  30. Mihajlovic M, Vlajkovic S, Jovanovic P, Stefanovic V. Primary mucosal melanomas: a comprehensive review. Int J Clin Exp Pathol 2012; 5 (8): 739-53.
  31. Seetharamu N, Ott P.A, Pavlick A.C. Mucosal melanomas: a case - based review of the literature. Oncologist 2010; 15 (7): 772-81. doi: 10.1634/theoncologist.2010-0067.
  32. Hodi F.S, Corless C.L, Giobbie-Hurder A et al. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun - damaged skin. J Clin Oncol 2013; 31 (26): 3182-90. doi: 10.1200/JCO.2012.47.7836.
  33. Guo J, Si L, Kong Y et al. Phase II, open - label, single - arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J Clin Oncol 2011; 29 (21): 2904-9. doi: 10.1200/JCO.2010.33.9275.
  34. Lutzky J, Bauer J, Bastian B. Dose - dependent, complete response to imatinib of ametastatic mucosal melanoma with a K642E KIT mutation. Pigm Cell Melanoma Res 2008; 21 (4): 492-3.
  35. Postow M.A, Luke J.J, Bluth M.J et al. Ipilimumab for patients with advanced mucosal melanoma. Oncologist 2013; 18 (6): 726-32. doi: 10.1634/theoncologist.2012-0464.
  36. Quintas-Cardama A, Lazar A.J, Woodman S.E et al. Complete response of stage IV anal mucosal melanoma expressing KIT Val560Asp to the multikinase inhibitor sorafenib. Nat Clin Pract Oncol 2008; 5 (12): 737-40. doi: 10.1038/ncponc1251.
  37. Woodman S.E, Trent J.C, Stemke-Hale K et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther 2009; 8 (8): 2079-85. doi: 10.1158/1535-7163. MCT-09-0459.
  38. Woodman S.E, Davies M.A. Targeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeutics. Biochem Pharmacol 2010; 80 (5): 568-74. doi: 10.1016/j.bcp.2010.04.032.
  39. Zhu Y.S.L, Kong Y, Chi Z et al. Response to sunitinib in Chinese KIT-mutated metastatic mucosal melanoma. J Clin Oncol 2009; 27 (15 s): e20017.
  40. Ascierto P.A, Minor D, Ribas A et al. Trefzer U. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J Clin Oncol 2013; 31 (26): 3205-11. doi: 10.1200/JCO.2013.49.8691.
  41. Chapman P.B, Hauschild A, Robert C et al. Group B-S. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364 (26): 2507-16. DOI: 10.1056/ NEJ Moa1103782.
  42. Akinleye A, Furqan M, Mukhi N et al. MEK and the inhibitors: from bench to bedside. J Hematol Oncol 2013; 6: 27. doi: 10.1186/1756-8722-6-27.
  43. Voskoboynik M, Arkenau H.T. Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int 2014; 2014: 307059. doi: 10.1155/2014/ 307059.

Copyright (c) 2016 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies